Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23302127 | 0.83 | SMN1; SMN2 (0.37) | MEN1KMT2ATP53SMN1; SMN2KDM4E | |
| SCHEMBL24978831 | 0.75 | MEN1 (0.52) | MEN1KMT2ATP53SMN1; SMN2KDM4E | |
| SCHEMBL23302264 | 0.75 | KDM4E (0.39) | SMN1; SMN2HSD11B1KDM4EALDH1A1 | |
| SCHEMBL29335773 | 0.75 | SMN1; SMN2 (0.40) | MEN1KMT2ATP53SMN1; SMN2KDM4E | |
| SCHEMBL23302128 | 0.72 | GRM2 (0.35) | — | |
| SCHEMBL23302158 | 0.71 | CHRNB2 (0.35) | — | |
| SCHEMBL22606823 | 0.71 | LPL (0.36) | — | |
| SCHEMBL21871418 | 0.69 | TRPA1 (0.45) | TP53 | |
| SCHEMBL16439291 | 0.67 | PRKCI (0.33) | HSD11B1 | |
| SCHEMBL28080069 | 0.66 | MEN1 (0.47) | MEN1KMT2ATP53SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4329750-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232320-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246968-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | MEN1 498/4885KMT2A 1172/4885TP53 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.